Adoptive transfer of immature myeloid cells lacking NF‐κB p50 (p50‐IMC) impedes the growth of MHC‐matched high‐risk neuroblastoma

Cui, Cheng; Barberi, Theresa J.; Suresh, Rahul; Friedman, Alan D.

doi:10.1002/1878-0261.12904

Cited by 2 publications

(3 citation statements)

References 38 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following mechanism seems to govern the potentiation of tumor growth inhibitory activity of the checkpoint inhibitor PD-1 [18]. The PD-1 antibody binding to PD-1 on T-cells prevents T-cells from receiving an inhibitory signal from PD-1 ligands (PDL1 and PDK2) expressed on cancer and on myeloid such as macrophages present in the tumor.…”

Section: Discussionmentioning

confidence: 99%

“…Immune checkpoint inhibitors such as PD-1 that active exhausted antitumor T cells are used alone or with chemotherapy for the treatment of a wide range of cancers [16] [17] [18] [19]. To our knowledge, immune checkpoint inhibitors have not previously been evaluated in combination with anticancer functional foods such as the bioprocessed black rice bran.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bioprocessed Black Rice Bran Potentiates the Growth Inhibitory Activity of an Immune Checkpoint Inhibitor against Murine Colon Carcinoma

Lee,

Kwon,

Hwang

et al. 2023

FNS

View full text Add to dashboard Cite

This study determined the effect of orally fed polysaccharide-rich bioprocessed (fermented) black rice bran produced by culturing with shiitake (Lentinus edodes) mushroom mycelium on CT-26 colon cancer cells in vivo in an intracutaneously transplanted mouse tumor alone and in combination with intraperitoneally administered anti-PD-1 immune checkpoint inhibitor. Analysis of the isolated tumor weights at the end of the study shows that the average tumor size in control mice is 3.78 grams, and the average tumor size in mice treated with anti-PD-1 antibody is 2.16 grams. The average tumor size in mice treated with BRB-F alone is 2.25 grams, and the average tumor size in mice treated with anti-PD-1 antibody BRB-F combination is 1.38 grams. Thus, BRB-F or anti-PD-1 antibody alone each reduce tumor size by 40.5% or 42.9%, whereas the combination of BRB-F and anti-PD-1 antibody reduces tumor size by 63.5%, with their cooperative effect being statistically significant. The observed anti-tumor effects were accompanied by a series of biomarkers associated with cancer formation and inhibition. These results indicate that the reported potentiation of cancer therapy using drug-based medical chemotherapies with added checkpoint inhibitors in human patients are mechanistically similar with the functional food evaluated in the present study. These beneficial effects in mice challenge clinicians to investigate if the black rice bran food product can also protect against human cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Bioprocessed Black Rice Bran Potentiates the Growth Inhibitory Activity of an Immune Checkpoint Inhibitor against Murine Colon Carcinoma

Lee,

Kwon,

Hwang

et al. 2023

FNS

View full text Add to dashboard Cite

show abstract

“…We were surprised and disappointed that RT + anti-GD2 immunocytokine (IC) + anti-CTLA-4 did not slow the progressive growth of this tumor any more than the minimal slowing seen with 12 Gy RT alone. Several other immunotherapy (and other novel) regimens have been used on mice bearing this "cold" 9464D-GD2 neuroblastoma, and for the most, part tumor growth could be slowed in vivo, but rarely could mice be cured of measurable 9464D-GD2 tumors due to a variety of proposed mechanisms of resistance [14][15][16][17][18][19][20][21][22][23]. This refractory behavior was consistent with the low tumor mutation burden of this NBL (1/10 that of the B78 melanoma) [13], and consistent with the observation of potentially inhibitory macrophages and myeloid elements in this (and other) NBLs [24].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy

Zebertavage,

Schopf,

Nielsen

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Incorporating GD2-targeting monoclonal antibody into post-consolidation maintenance therapy has improved survival for children with high-risk neuroblastoma. However, ~50% of patients do not respond to, or relapse following, initial treatment. Here, we evaluated additional anti-GD2-based immunotherapy to better treat high-risk neuroblastoma in mice to develop a regimen for patients with therapy-resistant neuroblastoma. Methods: We determined the components of a combined regimen needed to cure mice of established MYCN-amplified, GD2-expressing, murine 9464D-GD2 neuroblastomas. Results: First, we demonstrate that 9464D-GD2 is nonresponsive to a preferred salvage regimen: anti-GD2 with temozolomide and irinotecan. Second, we have previously shown that adding agonist anti-CD40 mAb and CpG to a regimen of radiotherapy, anti-GD2/IL2 immunocytokine and anti-CTLA-4, cured a substantial fraction of mice bearing small 9464D-GD2 tumors; here, we further characterize this regimen by showing that radiotherapy and hu14.18-IL2 are necessary components, while anti-CTLA-4, anti-CD40, or CpG can individually be removed, and CpG and anti-CTLA-4 can be removed together, while maintaining efficacy. Conclusions: We have developed and characterized a regimen that can cure mice of a high-risk neuroblastoma that is refractory to the current clinical regimen for relapsed/refractory disease. Ongoing preclinical work is directed towards ways to potentially translate these findings to a regimen appropriate for clinical testing.

show abstract

Adoptive transfer of immature myeloid cells lacking NF‐κB p50 (p50‐IMC) impedes the growth of MHC‐matched high‐risk neuroblastoma

Abstract: High-risk neuroblastomas harbor abundant myeloid cells that suppress anti-tumor immunity and support tumor growth. Macrophages lacking the inhibitory NF-κB p50 subunit adopt a pro-

Cited by 2 publications

References 38 publications

Bioprocessed Black Rice Bran Potentiates the Growth Inhibitory Activity of an Immune Checkpoint Inhibitor against Murine Colon Carcinoma

Bioprocessed Black Rice Bran Potentiates the Growth Inhibitory Activity of an Immune Checkpoint Inhibitor against Murine Colon Carcinoma

Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy

Contact Info

Product

Resources

About